X-Rx Discovery, Inc.
430 East 29th Street
Suite 1060
New York
New York
10016
United States
Website: http://www.x-rxdiscovery.com/
About X-Rx Discovery, Inc.
X-Rx is a discovery-stage company with the capabilities and know-how to discover and develop first- and best-in-class small molecule medicines in a manner that is rapid, cost-effective and high quality.Founded in 2012 by PPD as majority owner, X-Rx is a biotech company with more than 80 years of combined drug discovery and development experience. Together and in partnership with a number of CROs, we focus on the creation of pre-clinical small molecule drug candidates in a manner that is rapid, efficient and high quality. With access to the industry’s best DNA-encoded library screening platform, we are able to address difficult to drug targets, many of which are highly validated and offer first-in–class opportunities. Our primary disease areas are oncology, autoimmunity and fibrosis.
YEAR FOUNDED:
2012
LEADERSHIP:
CEO: Lee E. Babiss
CFO: Jeffrey Troderman
CLINICAL TRIAL:
Please click here for clinical trial information.
2 articles about X-Rx Discovery, Inc.
-
X-Rx Announces FDA Acceptance of IND Application for X-165
1/24/2019
X-Rx, Inc., announced the US Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) for X-165 being developed for the treatment of Idiopathic Pulmonary Fibrosis.
-
X-Rx And Mercachem Provide Update On Two Discovery-Stage Oncology Programs
10/26/2016